The combination of histopathological parameters, expression patterns of hormone receptors (Oestrogen and/or Progesterone Receptors; ER/PR) and Epidermal Growth Factor Receptor 2 (HER2/neu), and genomic and transcriptomic profile data brought to light the existence of several breast cancer subtypes. This evidence concerns the gene ERBB2 and breast cancer.